Skip to main content
Fig. 6 | Alzheimer's Research & Therapy

Fig. 6

From: Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

Fig. 6

Metabolite comparison between mild cognitive impairment subgroups. Boxplots highlighting differences between metabolite concentrations in serum when comparing two subgroups of participants with a baseline clinical diagnosis of mild cognitive impairment (MCI). The first group (blue) remained cognitively stable throughout follow-up study visits (stable MCI (sMCI)), whilst the second group (yellow) experienced a deterioration in cognition and converted to a clinical diagnosis of AD at follow-up (converting MCI (cMCI)). Boxplots are only presented for the metabolites in the serotonin and kynurenine pathways that reported significant differences between control, MCI and AD participant groups in phases 1 and 2 of the study (Supplementary Figs. S1 and S2). No significant differences were observed between the sMCI and cMCI groups in this study

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193